ID
45160
Beschreibung
Principal Investigator: Mark A. Rubin, MD, Weill Cornell Medical College, New York, NY, USA MeSH: Prostatic Neoplasms https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs000311 We have developed FusionSeq to identify fusion transcripts from paired-end RNA-sequencing. FusionSeq includes filters to remove spurious candidate fusions with artifacts such as misalignments or random pairing of transcript fragments and it ranks candidates according to several statistics. It also has a module to identify exact sequences at breakpoint junctions. FusionSeq detected known and novel fusions in a specially sequenced calibration data set, including 8 cancers with and without known rearrangements.
Link
Stichworte
Versionen (2)
- 28.08.22 28.08.22 - Simon Heim
- 12.10.22 12.10.22 - Adrian Schulz
Rechteinhaber
Mark A. Rubin, MD, Weill Cornell Medical College, New York, NY, USA
Hochgeladen am
12. Oktober 2022
DOI
Für eine Beantragung loggen Sie sich ein.
Lizenz
Creative Commons BY 4.0
Modell Kommentare :
Hier können Sie das Modell kommentieren. Über die Sprechblasen an den Itemgruppen und Items können Sie diese spezifisch kommentieren.
Itemgroup Kommentare für :
Item Kommentare für :
Um Formulare herunterzuladen müssen Sie angemeldet sein. Bitte loggen Sie sich ein oder registrieren Sie sich kostenlos.
dbGaP phs000311 FusionSeq: Finding Fusions with Paired-End RNA-Seq
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, consent group, and affection status of participants with prostate cancer.
- Sample ID and sample source of participants with prostate cancer.
- Subject age, height, and family history of participants with prostate cancer.
- Sample ID, sample and tumor characteristics including tumor stage, grade, location, and sample type of participants with prostate cancer.
Ähnliche Modelle
Eligibility Criteria
- StudyEvent: SEV1
- Eligibility Criteria
- Subject ID, subject source, consent group, and affection status of participants with prostate cancer.
- Sample ID and sample source of participants with prostate cancer.
- Subject age, height, and family history of participants with prostate cancer.
- Sample ID, sample and tumor characteristics including tumor stage, grade, location, and sample type of participants with prostate cancer.
C0586597 (UMLS CUI [1,2])
C2922133 (UMLS CUI [1,3])
C0027651 (UMLS CUI [1,4])
C1268672 (UMLS CUI [1,5])
C1512693 (UMLS CUI [2,1])
C0012854 (UMLS CUI [2,2])
C0370003 (UMLS CUI [2,3])
C0586597 (UMLS CUI [2,4])
C0178913 (UMLS CUI [2,5])
C0332152 (UMLS CUI [2,6])
C0033573 (UMLS CUI [2,7])